A drug's life: The pathway to drug approval

Clinical Advances in Hematology and Oncology

Volumn 11, Issue 10, 2013, Pages 646-655

  Keng, Michael K ^a   Wenzell, Candice M ^c   Sekeres, Mikkael A ^b  

^a Hematology and medical oncology ^*  (United States)

^b TAUSSIG CANCER INSTITUTE   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Decitabine; Drug approval; Imatinib; Oncologic drugs advisory committee; Oncology drugs; US food and drug administration

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ALPHA INTERFERON; AXITINIB; BEVACIZUMAB; CYTARABINE; DARATUMUMAB; IMATINIB; LAMBROLIZUMAB; PACLITAXEL; PALBOCICLIB; SORAFENIB; SUNITINIB; THALIDOMIDE; TIVOZANIB;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; BREAST CANCER; DRUG APPROVAL; DRUG DESIGN; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; FOOD AND DRUG ADMINISTRATION; FUNDING; HUMAN; KIDNEY CARCINOMA; LOW DRUG DOSE; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; MYELOMA; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PHOCOMELIA; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC);

DRUG APPROVAL; HUMANS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84887067713     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Cramp AJ. Nostrums and Quackery. Chicago, IL: American Medical Association; 1921:832.
2. McNamara B. Step Right Up. Garden City, NY: Doubleday & Company, Inc; 1975:272.
3. Sweet BV, Schwemm AK, Parsons DM. Review of the processes for FDA oversight of drugs, medical devices, and combination products. J Manag Care Pharm. 2011;17(1):40-50.
4. Hayes TA. Te Food and Drug Administration's regulation of drug labeling, advertising, and promotion: looking back and looking ahead. Clin Pharmacol Ter. 1998;63(6):607-616.
5. Federal Food and Drugs Act of 1906. US Food and Drug Administration. http://www.fda.gov/RegulatoryInformation/Legislation/ucm148690.htm. Updated May 2009. Accessed May 19, 2013.
6. Legislation. US Food and Drug Administration. http://www.fda.gov/Regulatory-Information/Legislation/default.htm. Updated July 9, 2012. Accessed May 19, 2013.
7. Annas GJ, Elias S. Talidomide and the Titanic: reconstructing the technology tragedies of the twentieth century. Am J Public Health. 1999;89(1):98-101.
8. Derbis J, Evelyn B, McMeekin J. FDA aims to remove unapproved drugs from market: Risk-based enforcement program focuses on removing potentially harmful products. Pharmacy Today. 2008;v:21-22.
9. Orphan Drug Act. US Food and Drug Administration. Updated October 19, 2011. Accessed May 19, 2013. http://www.fda.gov/RegulatoryInformation/Leg-islation/FederalFoodDrugandCosmeticActFDCAct/SignifcantAmendmentsto-theFDCAct/OrphanDrugAct/default.htm
10. Developing products for rare diseases & conditions. US Food and Drug Administration. http://www.fda.gov/ForIndustry/DevelopingProductsforRareDis-easesConditions/default.htm. Updated May 29, 2013. Accessed May 29, 2013.
11. Expanded access and expedited approval of new therapies related to HIV/ AIDS. US Food and Drug Administration. http://www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/HIVandAIDSActivities/ucm134331.htm. Updated September 11, 2009. Accessed May 19, 2013.
12. Dagher R, Johnson J, Williams G, Keegan P, Pazdur R. Accelerated approval of oncology products: a decade of experience. J Natl Cancer Inst. 2004;96(20):1500-1509.
13. PDUFA legislation and background. US Food and Drug Administration. http://www.fda.gov/ForIndustry/UserFees/PrescriptionDrugUserFee/ucm144411.htm. Updated February 22, 2013. Accessed May 19, 2013.
14. Prescription Drug User Fee Act (PDUFA) of 1992. US Food and Drug Administration. http://www.fda.gov/RegulatoryInformation/Legislation/FederalFoodDru-gandCosmeticActFDCAct/SignifcantAmendmentstotheFDCAct/ucm147983.htm. Updated May 20, 2009. Accessed May 19, 2013.
15. Full text of FDAMA law. US Food and Drug Administration. http://www.fda.gov/RegulatoryInformation/Legislation/FederalFoodDrugandCosmeticActFD-CAct/SignificantAmendmentstotheFDCAct/FDAMA/FullTextofFDAMAlaw/ default.htm. Updated October 22, 2009. Accessed May 19, 2013.
16. Best Pharmaceuticals for Children Act. US Food and Drug Administration. http://www.fda.gov/RegulatoryInformation/Legislation/FederalFoodDrugand-CosmeticActFDCAct/SignifcantAmendmentstotheFDCAct/ucm148011.htm#. Updated May 20, 2009. Accessed May 19, 2013.
17. Food and Drug Administration Amendments Act (FDAAA) of 2007. US Food and Drug Administration. http://www.fda.gov/RegulatoryInformation/Leg-islation/FederalFoodDrugandCosmeticActFDCAct/SignifcantAmendmentsto-theFDCAct/FoodandDrugAdministrationAmendmentsActof2007/default.htm. Updated December 2, 2011. Accessed May 19, 2013.
18. Food and Drug Administration Safety and Innovation Act (FDASIA). US Food and Drug Administration. http://www.fda.gov/RegulatoryInformation/Legislation/FederalFoodDrugandCosmeticActFDCAct/SignificantAmend-mentstotheFDCAct/FDASIA/default.htm. Updated November 27, 2012. Accessed May 19, 2013.
19. Fact sheet: New user fees for generic drugs will enhance Americans' access to less expensive drugs and generate major cost savings. US Food and Drug Administration. http://www.fda.gov/RegulatoryInformation/Legislation/FederalFood-DrugandCosmeticActFDCAct/SignifcantAmendmentstotheFDCAct/FDASIA/ ucm310992.htm. Updated September 17, 2012. Accessed May 19, 2013.
20. Fact sheet: New "biosimilars" user fees will enhance Americans' access to alternatives to biologic drugs. US Food and Drug Administration. http://www.fda.gov/RegulatoryInformation/Legislation/FederalFoodDrugandCosmeticActFDCAct/SignifcantAmendmentstotheFDCAct/FDASIA/ucm311121.htm. Updated July 16, 2012. Accessed May 19, 2013.
21. Fact sheet: Pediatric provisions in the Food and Drug Administration Safety and Innovation Act (FDASIA). US Food and Drug Administration. http://www.fda.gov/RegulatoryInformation/Legislation/FederalFoodDrugandCosmeti-cActFDCAct/SignifcantAmendmentstotheFDCAct/FDASIA/ucm311038.htm. Updated July 9, 2012. Accessed May 19, 2013.
22. Fact sheet: Breakthrough therapies. US Food and Drug Administration. http://www.fda.gov/RegulatoryInformation/Legislation/FederalFoodDrugandCosmeti-cActFDCAct/SignifcantAmendmentstotheFDCAct/FDASIA/ucm329491.htm. Updated February 27, 2013. Accessed May 19, 2013.
23. Frequently asked questions: Breakthrough therapies. US Food and Drug Administration. http://www.fda.gov/RegulatoryInformation/Legislation/FederalFood-DrugandCosmeticActFDCAct/SignificantAmendmentstotheFDCAct/FDASIA/ ucm341027.htm. Updated April 8, 2013. Accessed May 19, 2013.
24. The FDA's drug review process: Ensuring drugs are safe and effective. US Food and Drug Administration. http://www.fda.gov/Drugs/ResourcesForYou/Consum-ers/ucm143534.htm. Updated May 1, 2012. Accessed May 19, 2013.
25. New drug development and review process. US Food and Drug Administration. http://www.fda.gov/Drugs/DevelopmentApprovalProcess/SmallBusinessAs-sistance/ucm053131.htm. Updated August 28, 2012. Accessed May 19, 2013.
26. Molzon J. Te common technical document: the changing face of the New Drug Application. Nat Rev Drug Discov. 2003;2(1):71-74.
27. FDA's drug review process: continued. US Food and Drug Administration. http://www.fda.gov/Drugs/ResourcesForYou/Consumers/ucm289601.htm. Updated March 13, 2012. Accessed May 19, 2013.
28. Fast track, accelerated approval and priority review accelerating availability of new drugs for patients with serious diseases. US Food and Drug Administration. http://www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/SpeedingAccesstoImportant-NewTerapies/ucm128291.htm. Updated August 2, 2012. Accessed May 19, 2013.
29. Kantarjian HM, Deisseroth A, Kurzrock R, Estrov Z, Talpaz M. Chronic myelogenous leukemia: a concise update. Blood. 1993;82(3):691-703.
30. Faderl S, Talpaz M, Estrov Z, O'Brien S, Kurzrock R, Kantarjian HM. Te biology of chronic myeloid leukemia. N Engl J Med. 1999;341(3):164-172.
31. Cohen MH, Moses ML, Pazdur R. Gleevec for the treatment of chronic myelog-enous leukemia: US. Food and Drug Administration regulatory mechanisms, accelerated approval, and orphan drug status. Oncologist. 2002;7(5):390-392.
32. Deininger MW, Goldman JM, Melo JV. Te molecular biology of chronic myeloid leukemia. Blood. 2000;96(10):3343-3356.
33. Cohen MH, Williams G, Johnson JR, et al. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res. 2002;8(5):935-942.
34. Johnson JR, Bross P, Cohen M, et al. Approval summary: imatinib mesylate capsules for treatment of adult patients with newly diagnosed philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase. Clin Cancer Res. 2003;9(6):1972-1979.
35. Cohen MH, Johnson JR, Pazdur R. U.S. Food and Drug Administration Drug Approval Summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval. Clin Cancer Res. 2005;11(1):12-19.
36. Talpaz M, Silver RT, Druker BJ, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood. 2002;99(6):1928-1937.
37. Sawyers CL, Hochhaus A, Feldman E, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood. 2002;99(10):3530-3539.
38. Kantarjian HM, Talpaz M, O'Brien S, et al. Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-α: follow-up results. Clin Cancer Res. 2002;8(7):2177-2187.
39. Soverini S, Martinelli G, Iacobucci I, Baccarani M. Imatinib mesylate for the treatment of chronic myeloid leukemia. Expert Rev Anticancer Ter. 2008;8(6):853-864.
40. O'Brien SG, Guilhot F, Larson RA, et al; IRIS Investigators. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348(11):994-1004.
41. Druker BJ, Guilhot F, O'Brien SG, et al; IRIS Investigators. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355(23):2408-2417.
42. Meeting of the Oncologic Drugs Advisory Committee - FDA ODAC briefing document for decitabine, February 9, 2012. US Food and Drug Administration. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMa-terials/Drugs/OncologicDrugsAdvisoryCommittee/UCM290512.pdf. Accessed May 30, 2013.
43. Estey EH. Advances in the management of AML in the elderly. Clin Adv Hematol Oncol. 2007;5(3):185-187.
44. Cashen A F, Schiller GJ, O'Donnell MR, DiPersio JF. Multicenter, phase II study of decitabine for the frst-line treatment of older patients with acute myeloid leukemia. J Clin Oncol. 2010;28(4):556-561.
45. Kantarjian HM, Tomas XG, Dmoszynska A, et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol. 2012;30(21):2670-2677.
46. Sekeres MA, Steensma DP. Boulevard of broken dreams: drug approval for older adults with acute myeloid leukemia. J Clin Oncol. 2012;30(33):4061-4063.
47. Kantarjian H, Wilson W, Ravandi F, Estey E. Decitabine in older adults with acute myeloid leukemia: why was the dream broken? J Clin Oncol. 2013;31(14):1795-1796.
48. Meeting of the Oncologic Drugs Advisory Committee, February 9, 2012. US Food and Drug Administration. http://www.fda.gov/downloads/AdvisoryCom-mittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommit-tee/UCM298512.pdf. Accessed May 30, 2013.
49. Oncologic Drugs Advisory Committee. US Food and Drug Administration. http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ OncologicDrugsAdvisoryCommittee/default.htm. Updated May 27, 2011. Accessed May 31, 2013.
50. Motzer RJ, Nosov D, Eisen T, et al. Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: results from a phase III randomized, open-label, multicenter trial [ASCO abstract 4501]. J Clin Oncol. 2012;30(15 suppl).
51. Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet. 2011;378(9807):1931-1939.
52. Meeting of the Oncologic Drugs Advisory Committee, February 8, 2011. US Food and Drug Administration. http://www.fda.gov/downloads/AdvisoryCom-mittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommit-tee/UCM245644.pdf. Accessed May 30, 2013.
53. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus pacli-taxel alone for metastatic breast cancer. N Engl J Med. 2007;357(26):2666-2676.